15 Essential Pharmaceuticals Stories for Industry Leaders

Pharmaceuticals and life sciences dominate today's print media monitoring landscape, with fifteen developments reshaping India's drug and biotech sector. According to Press Monitor's tracking of Indian publications, this press review delivers the media intelligence and news on pharmaceuticals that industry leaders need to act on today.

1. Emcure Pharma and Kissht Buy Calls

A front-page report in Business Line says ICICI Direct recommended buying Pune-headquartered Emcure Pharmaceuticals at a target price of Rs 2,305 per share, above its current market price of Rs 1,928.55, while JM Financial recommended buying OnEMI Technology Solutions, also known as Kissht, at a target price of Rs 385 per share, above its current market price of Rs 309.10. Issued on 18 July 2026, the India-market recommendations cite Emcure's diversified pharmaceutical portfolio and international expansion, and Kissht's digital lending growth and improving credit profile. Tracked by Press Monitor — ICICI Direct's buy call on Emcure Pharmaceuticals at a target of Rs 2,305 per share signals confidence in the company's diversified portfolio and international expansion. JM Financial's parallel buy call on Kissht highlights the growing intersection of pharma and digital finance. Why it matters: Brokerage endorsements from major Indian firms can shift institutional capital flows overnight. Key detail: Emcure's current market price is Rs 1,928.55 against a target of Rs 2,305. Source: Business Line. Next step: Monitor Emcure's quarterly guidance for alignment with analyst expectations.

2. Dadachanji Group Re-enters Pharma Glass Packaging

A front-page report in Business Line says the Dadachanji Group has re-entered pharmaceutical glass packaging with the launch of Kaisha Pharma, five years after it exited the Schott Kaisha joint-venture. The group has made an initial investment of €45 million to scale up its operational capabilities with a more global approach compared to its earlier India-focused operations. Kaisha Pharma is entering the market with a portfolio of tubular glass products including ampoules, vials, prefilled syringes and cartridges, and is setting up an international business development office in Europe. The Dadachanji Group's €45 million launch of Kaisha Pharma marks a strategic return to pharmaceutical glass packaging after exiting the Schott Kaisha joint venture five years ago. With an international business development office in Europe, the move signals India's ambition to capture a larger share of global pharma packaging. Why it matters: Primary packaging is a critical bottleneck for biotech and biologic drug manufacturers. Key detail: €45 million initial investment targeting Indian and global pharma and biotech companies. Source: Business Line. Next step: Watch for Kaisha Pharma's first commercial contracts with biologics firms.

3. Personalised mRNA Vaccines Target Melanoma

A front-page report in Statesman says that personalised mRNA vaccines against melanoma have shown the strongest indication yet that the immune system can be trained to recognise the unique genetic signature of a tumour and prevent the disease from returning. The approach uses tumour sequencing to identify abnormalities and design a vaccine that teaches the body's defences to hunt down residual malignant cells. While caution remains because encouraging results in melanoma do not amount to a universal cure, the broader direction marks a shift towards therapies tailored to the molecular identity of individual tumours. Statesman reports that personalised mRNA vaccines against melanoma have demonstrated the strongest indication yet that the immune system can be trained to recognise a tumour's unique genetic signature. The approach uses tumour sequencing to design vaccines that teach the body's defences to hunt residual malignant cells. Why it matters: This represents a paradigm shift toward precision oncology with implications for Indian biotech firms investing in mRNA platforms. Key detail: The vaccine approach identifies tumour abnormalities through sequencing and designs targeted immune responses. Source: Statesman. Next step: Track clinical trial partnerships between Indian pharma companies and mRNA technology providers.

4. IIT-Gandhinagar Study Targets Drug-Resistant Staph

A front-page report in Free Press Journal says researchers from IIT Gandhinagar and partner institutions have developed DSA3, a laboratory-made molecule that targets thymidine kinase, an enzyme essential for bacterial DNA replication. The study, published in Chemistry & Biodiversity and funded by the Indian Council of Medical Research, provides an early proof of concept for attacking methicillin-resistant Staphylococcus aureus, a major drug-resistant threat. Researchers stressed that DSA3 remains far from becoming a medicine and is a proof of concept and starting scaffold requiring further work. IIT Gandhinagar researchers have developed DSA3, a laboratory-made molecule targeting thymidine kinase to combat methicillin-resistant Staphylococcus aureus. Funded by the Indian Council of Medical Research and published in Chemistry & Biodiversity, the study offers early proof of concept against one of India's most pressing antimicrobial resistance threats. Why it matters: Drug-resistant infections cost Indian hospitals billions annually. Key detail: DSA3 targets thymidine kinase, an enzyme essential for bacterial DNA replication. Source: Free Press Journal. Next step: Follow DSA3's progression from proof of concept to preclinical trials.

5. Stegodyphus Venom Anti-Cancer

A front-page report in The Hindu says Indian researchers have mapped the venom gland of the colonial spider Stegodyphus sarasinorum, identifying over a hundred proteins and metabolites with potential anti-cancer, antimicrobial and immune-related activities. The study, published in Scientific Reports by Springer, showed that venom extracts killed Dalton’s Lymphoma Ascites cancer cells in laboratory experiments. The researchers caution that further validation is needed before clinical use. The Hindu reports that Indian researchers have mapped the venom gland of the colonial spider Stegodyphus sarasinorum, identifying over a hundred proteins with potential anti-cancer activity. Laboratory experiments showed venom extracts killed Dalton's Lymphoma Ascites cancer cells. Why it matters: Spider venom-derived compounds could open a new frontier in oncology drug discovery. Key detail: Over a hundred proteins and metabolites identified with anti-cancer, antimicrobial and immune-related activities. Source: The Hindu. Next step: Monitor for biotech licensing deals emerging from this research.

6. 3 Arrested In Fake Nicardia Ring

A front-page report in Free Press Journal says three people were arrested in a joint operation by the Ahmedabad Crime Branch and Gujarat Food and Drugs Control Administration. The case emerged after pharmaceutical firm J.B. Chemicals and Pharmaceuticals alleged that fake copies of its blood-pressure pill Nicardia Retard 10 were being circulated. Investigators traced the suspect supply chain through medical distributors across Gujarat before linking it to operations in Lucknow. Free Press Journal reports that three people were arrested in a joint operation by the Ahmedabad Crime Branch and Gujarat Food and Drugs Control Administration after J.B. Chemicals alleged counterfeit copies of its blood-pressure pill Nicardia Retard 10 were circulating through Gujarat and Lucknow. Why it matters: Counterfeit medicines pose a direct threat to patient safety and brand integrity across the pharmaceutical supply chain. Key detail: Suspect supply chain traced through medical distributors across Gujarat before linking to operations in Lucknow. Source: Free Press Journal. Next step: Pharma companies should strengthen track-and-trace systems in response to rising counterfeit incidents.

7. Delhi Govt Bans Exaggerated 80% Discount Ads

A front-page report in Hindustan Times says the Delhi Drugs Control Department directed pharmacies to stop displaying unrealistic discount claims following concerns about drug genuineness. Officials cited a Kerala High Court judgment to justify the advisory against vague pricing. The Delhi Drugs Control Department has directed pharmacies to stop displaying unrealistic discount claims, citing concerns about drug genuineness and a Kerala High Court judgment. Why it matters: Regulatory tightening on pharmacy marketing could reshape how pharmaceutical products are promoted at the retail level. Key detail: Officials cited a Kerala High Court judgment to justify the advisory against vague pricing. Source: Hindustan Times. Next step: Pharmacy chains should review their advertising compliance ahead of the advisory.

8. Delhi Air Pollution Carries Antibiotic-Resistant Bacteria

A front-page report in Deccan Herald says a study led by Professor Kasturi Mukhopadhyay at Jawaharlal Nehru University found high levels of antibiotic-resistant bacteria in Delhi's polluted air. The research suggests fine particulate matter may carry microbes deeper into lungs where biofilms help them evade antibiotics, worsening COPD and potentially linking to lung cancer. Experts note reducing pollution exposure and early diagnosis remain key priorities while microbiome-based treatments show promise. A JNU study led by Professor Kasturi Mukhopadhyay found high levels of antibiotic-resistant bacteria in Delhi's polluted air, with fine particulate matter potentially carrying microbes deeper into lungs where biofilms help them evade antibiotics. Why it matters: This environmental-health intersection adds a new dimension to antimicrobial resistance policy. Key detail: Research suggests fine particulate matter may carry microbes deeper into lungs where biofilms help them evade antibiotics, worsening COPD and potentially linking to lung cancer. Source: Deccan Herald. Next step: Public health agencies should integrate air quality data into antibiotic resistance surveillance.

9. AP Demands Ethanol Sanitiser Sales Restrictions

A front-page report in The Hans India says the Andhra Pradesh Drugs Control Administration has requested tighter controls on ethanol-based hand sanitisers following reports of their misuse as an alcoholic substitute. Director General P Arun Babu highlighted that exemptions granted during the twenty-twenty pandemic remain active and are being exploited, citing inspections where retailers moved more than thirty-three thousand five hundred eighty-six bottles. Authorities have initiated licence cancellation proceedings against three outlets while urging federal officials to revoke the sales waiver. The Andhra Pradesh Drugs Control Administration has requested tighter controls on ethanol-based hand sanitisers, citing misuse as an alcoholic substitute. Director General P Arun Babu noted that over 33,586 bottles were moved by retailers exploiting pandemic-era exemptions. Why it matters: Regulatory crackdowns on sanitiser misuse reflect broader drug control enforcement trends. Key detail: Three outlets face licence cancellation proceedings while authorities urge federal officials to revoke the sales waiver. Source: The Hans India. Next step: Consumer goods companies should prepare for potential federal policy changes.

10. Bengaluru Biomedical Waste in Grey Zone

A front-page report in Deccan Herald says Bengaluru lacks a collection and disposal system for household biomedical waste, with expired drugs worth Rs 23.03 crore found undisposed of at 27 district warehouses across Karnataka between 2019 and 2022. The Bangalore District Chemists and Druggists Association has written to the Drug Controller General of India seeking clarifications on the Central Drugs Standard Control Organisation guidance document, while the Karnataka State Pollution Control Board is working on a dashboard to track biomedical waste. Deccan Herald reports that Bengaluru lacks a collection and disposal system for household biomedical waste, with expired drugs worth Rs 23.03 crore found undisposed at 27 district warehouses across Karnataka between 2019 and 2022. Why it matters: Improper pharmaceutical waste disposal creates environmental and public health risks that regulators are increasingly scrutinising. Key detail: Rs 23.03 crore in expired drugs found undisposed at 27 district warehouses across Karnataka between 2019 and 2022. Source: Deccan Herald. Next step: Pharma companies operating in Karnataka should engage with the Karnataka State Pollution Control Board's new tracking dashboard.

11. NIPER Guwahati Announces Secretary Recruitment 2026

A front-page report in Indian Express says the National Institute of Pharmaceutical Education and Research Guwahati has invited applications for the post of Secretary to Registrar on a regular basis from eligible Indian nationals. The online application window opens on twenty-first August twenty twenty six at eleven in the morning, with the final deadline for online submission and fee payment set for nineteenth September twenty twenty six at five in the evening. Candidates must submit the hard copy of their application along with all enclosures by twenty-sixth September twenty twenty six at five in the evening, with full qualification details available on the institute website. Indian Express reports that NIPER Guwahati has invited applications for the post of Secretary to Registrar, with the online application window opening on 21 August 2026. Why it matters: Government pharmaceutical education institutions are expanding administrative capacity, signaling investment in the sector's talent pipeline. Key detail: Online application opens 21 August 2026 with final deadline for submission on 19 September 2026. Source: Indian Express. Next step: Qualified candidates should apply before the 19 September 2026 deadline.

12. Belgium Warns Europe on China Dependence

A front-page report in First India says Belgian Prime Minister Bart De Wever admitted Europe saw the risks of economic dependence on China but failed to listen to India. He stressed that free trade must remain open but cannot mean being naive about economic coercion. Europe is now seeking strategic diversification through deeper cooperation with India in critical minerals, semiconductors, technology, pharmaceuticals, energy and defence. Belgian Prime Minister Bart De Wever stated that Europe is seeking strategic diversification through deeper cooperation with India in critical areas including pharmaceuticals. Why it matters: European pharma companies may increasingly look to India for supply chain partnerships and API sourcing. Key detail: Europe is seeking strategic diversification through deeper cooperation with India in critical minerals, semiconductors, technology, pharmaceuticals, energy and defence. Source: First India. Next step: Indian pharma exporters should prepare for increased European demand in critical minerals, technology, and pharmaceuticals.

13. Vulture Numbers Still Stagnate

A front-page report in Deccan Herald says that two decades after India banned the veterinary drug diclofenac, vulture numbers have not recovered. The assessment released on Vulture Awareness Day in 2026 highlights that the ban was not fully enforced and that other threats such as electrocution and poisoning remain. Conservationists from the Bombay Natural History Society and the Saving Asia's Vultures from Extinction consortium warn that the population decline continues. Two decades after India banned the veterinary drug diclofenac, vulture numbers have not recovered, according to a Deccan Herald assessment released on Vulture Awareness Day 2026. Why it matters: The diclofenac ban's enforcement gaps highlight challenges in pharmaceutical environmental impact regulation. Key detail: Conservationists from the Bombay Natural History Society and the Saving Asia's Vultures from Extinction consortium warn that the population decline continues. Source: Deccan Herald. Next step: Conservation and pharma regulatory bodies should coordinate on drug safety testing for wildlife.

14. Einstein Curiosity Nobel Prize Discovery

A front-page report in Free Press Journal says curiosity has driven major scientific discoveries throughout history. The article highlights Sir Chandrasekhara Venkata Raman's fascination with the Mediterranean Sea leading to the Raman Effect and the nineteen thirty Nobel Prize in Physics, Marie Curie's pioneering work in radioactivity, and Asima Chatterjee's contributions to Ayurvedic chemistry. These stories illustrate how patience, observation, and perseverance in scientific inquiry can transform the world. Free Press Journal highlights how curiosity drove discoveries including Sir Chandrasekhara Venkata Raman's Raman Effect, Marie Curie's radioactivity work, and Asima Chatterjee's contributions to Ayurvedic chemistry. Why it matters: India's legacy in scientific inquiry continues to inspire pharmaceutical and life sciences innovation. Key detail: Asima Chatterjee's contributions to Ayurvedic chemistry connect traditional medicine with modern pharmaceutical research. Source: Free Press Journal. Next step: Research institutions should leverage this narrative to attract funding for Ayurvedic and traditional medicine research.

15. DPSRU Open Counselling 2026-27

A front-page report in Times of India says Delhi Pharmaceutical Sciences and Research University is inviting fresh applications for admission under the Open Round of Counseling for the academic session 2026-27. The online application process covers unfilled vacancies in Diploma, Undergraduate (except B.Pharm and BPT), and Postgraduate programmes. Admission and counseling will be conducted in physical mode based on details available at www.dpsru.edu.in. Times of India reports that Delhi Pharmaceutical Sciences and Research University is inviting applications for admission under the Open Round of Counseling for 2026-27. Why it matters: Expanding pharmacy education capacity addresses India's growing need for qualified pharmaceutical professionals. Key detail: The online application process covers unfilled vacancies in Diploma, Undergraduate, and Postgraduate programmes. Source: Times of India. Next step: Prospective students should monitor www.dpsru.edu.in for unfilled vacancy details.

This print media intelligence review underscores the breadth of today's pharmaceutical news — from drug safety and regulation to innovation and education. Which development will you be tracking next?